CUMBERLAND PHARMACEUTICALS INC Q4 FY2024 earnings call

Business Strategy

• Cumberland's strategy is to acquire and commercialize branded pharmaceuticals, grow via domestic sales organization and international partnerships, and advance development pipeline. The Cumberland Emerging Technologies (CET) division, a joint initiative with Vanderbilt University, enhances the pipeline.

2024 Developments

• Positive Phase 2 study data for ifetroban in Duchenne muscular dystrophy.
• Vibativ approved in China and shipped to Saudi Arabia.
• Publication of real-world outcomes research for Caldolor vs Ketorolac.
• FDA approval of Acetadote's supplemental new drug application.
• Ifetroban received orphan drug and rare pediatric disease designations from FDA.
• Marketing initiatives for brands: Kristalose's Medicaid coverage expansion, Caldolor's pediatric labeling and sales/marketing initiatives, Sancuso's manufacturing transfer and sampling program.

For the three months ending December 31, 2024, net revenue from continuing operations was $10.4 million, representing an 11.6% increase over the prior year period. In the fourth quarter of 2024, net revenue by product was $4.4 million for Kristalose, $2.4 million for Sancuso, $2.1 million for Vibativ, and $1.4 million for Caldolor. For the full year 2024, net revenues were $38 million. Full-year product revenue was $15.3 million for Kristalose, $9 million for Sancuso, $6.9 million for Vibativ, and $5 million for Caldolor.

Forward-Looking Statements

• Cumberland expects to deliver double-digit revenue growth this year as well as positive cash flow from operations.

Risk Factors

• Factors that could affect future results include natural disasters, economic downturns, public health epidemics, international conflicts, trade restrictions, and other factors beyond the company's control.